Standard endocrine therapy

DRUG2 trials

Sponsors

ETOP IBCSG Partners Foundation, Shanghai Changzheng Hospital

Conditions

Breast Cancer RecurrentProstate Cancer AdenocarcinomamHNPCmHSPC

Early Phase 1

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Not yet recruitingNCT07389174

Shanghai Changzheng HospitalmHNPC, mHSPC, Prostate Cancer Adenocarcinoma

Start: 2026-02-01End: 2027-06-01Target: 40Updated: 2026-02-05

Phase 3

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Active, not recruitingNCT03820830

ETOP IBCSG Partners FoundationBreast Cancer Recurrent

Start: 2019-08-27End: 2029-01-01Updated: 2025-03-07

Related Papers

Abstract OT-26-02: Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial

Cancer Research2021-02-153 citations